OBJECTIVE: To assess patterns of morbidity and associated factors in late infancy and early childhood among human immunodeficiency virus (HIV)-infected and -uninfected African children. DESIGN: Prospective study. SETTING: The Queen Elizabeth Central Hospital, Blantyre, Malawi. PARTICIPANTS: Children with known HIV status from an earlier perinatal intervention trial were enrolled during the first year of life and followed to approximately 36 months of age. OUTCOME MEASURES: Morbidity and mortality information was collected every 3 months by a questionnaire. A physical examination was conducted every 6 months. Blood to determine CD4(+) values was also collected. Age-adjusted and Kaplan-Meier analyses were performed to compare rates of morbidity and mortality among infected and uninfected children. RESULTS: Overall, 808 children (190 HIV-infected, 499 HIV-uninfected but born to infected mothers, and 119 born to HIV-uninfected mothers) were included in this study. Of these, 109 died during a median follow-up of 18 months. Rates of childhood immunizations were high among all children (eg, lowest was measles vaccination [87%] among HIV-infected children). Age-adjusted morbidity rates were significantly higher among HIV-infected than among HIV-uninfected children. HIV-infected children were more immunosuppressed than were uninfected children. By 3 years of age, 89% of the infected children died, 10% were in HIV disease category B or C, and only approximately 1% were without HIV symptoms. Among HIV-infected children, median survival after the first occurrence of acquired immunodeficiency syndrome-related conditions, such as splenomegaly, oral thrush, and developmental delay, was <10 months. These same conditions, in addition to frequent bouts of fever, were the main morbidity predictors of mortality. CONCLUSIONS: The frequency of diseases was high, and progression from asymptomatic or symptomatic HIV disease to death was rapid. Management strategies that effectively reduce morbidity for HIV-infected children are needed.
OBJECTIVE: To assess patterns of morbidity and associated factors in late infancy and early childhood among human immunodeficiency virus (HIV)-infected and -uninfected African children. DESIGN: Prospective study. SETTING: The Queen Elizabeth Central Hospital, Blantyre, Malawi. PARTICIPANTS: Children with known HIV status from an earlier perinatal intervention trial were enrolled during the first year of life and followed to approximately 36 months of age. OUTCOME MEASURES: Morbidity and mortality information was collected every 3 months by a questionnaire. A physical examination was conducted every 6 months. Blood to determine CD4(+) values was also collected. Age-adjusted and Kaplan-Meier analyses were performed to compare rates of morbidity and mortality among infected and uninfected children. RESULTS: Overall, 808 children (190 HIV-infected, 499 HIV-uninfected but born to infected mothers, and 119 born to HIV-uninfected mothers) were included in this study. Of these, 109 died during a median follow-up of 18 months. Rates of childhood immunizations were high among all children (eg, lowest was measles vaccination [87%] among HIV-infectedchildren). Age-adjusted morbidity rates were significantly higher among HIV-infected than among HIV-uninfectedchildren. HIV-infectedchildren were more immunosuppressed than were uninfected children. By 3 years of age, 89% of the infected children died, 10% were in HIV disease category B or C, and only approximately 1% were without HIV symptoms. Among HIV-infectedchildren, median survival after the first occurrence of acquired immunodeficiency syndrome-related conditions, such as splenomegaly, oral thrush, and developmental delay, was <10 months. These same conditions, in addition to frequent bouts of fever, were the main morbidity predictors of mortality. CONCLUSIONS: The frequency of diseases was high, and progression from asymptomatic or symptomatic HIV disease to death was rapid. Management strategies that effectively reduce morbidity for HIV-infectedchildren are needed.
Authors: Taha E Taha; Donald R Hoover; Shu Chen; Newton I Kumwenda; Linda Mipando; Kondwani Nkanaunena; Michael C Thigpen; Allan Taylor; Mary Glenn Fowler; Lynne M Mofenson Journal: Clin Infect Dis Date: 2011-08 Impact factor: 9.079
Authors: Loukia Aketi; Pierre M Tshibassu; Patrick K Kayembe; Faustin Kitetele; Samuel Edidi; Mathilde B Ekila; Roger Wumba; François B Lepira; Michel N Aloni Journal: Pathog Glob Health Date: 2015-07-17 Impact factor: 2.894
Authors: Inácio Mandomando; Denise Naniche; Marcela F Pasetti; Lilian Cuberos; Sergi Sanz; Xavier Vallès; Betuel Sigauque; Eusébio Macete; Delino Nhalungo; Karen L Kotloff; Myron M Levine; Pedro L Alonso Journal: Am J Trop Med Hyg Date: 2011-07 Impact factor: 2.345
Authors: Edwin D Charlebois; Theodore D Ruel; Anne F Gasasira; Jane Achan; Frederick Kateera; Caroline Akello; Huyen Cao; Grant Dorsey; Philip J Rosenthal; Isaac Ssewanyana; Moses R Kamya; Diane V Havlir Journal: J Acquir Immune Defic Syndr Date: 2010-11 Impact factor: 3.731
Authors: Sharon Shalekoff; Stephen Meddows-Taylor; Glenda E Gray; Gayle G Sherman; Ashraf H Coovadia; Louise Kuhn; Caroline T Tiemessen Journal: AIDS Date: 2009-04-27 Impact factor: 4.177
Authors: Philippa M Musoke; Alicia M Young; Maxensia A Owor; Irene R Lubega; Elizabeth R Brown; Francis A Mmiro; Lynne M Mofenson; J Brooks Jackson; Mary Glenn Fowler; Laura A Guay Journal: J Acquir Immune Defic Syndr Date: 2008-10-01 Impact factor: 3.731